[Click eStock] "Cytogen, Unique CTC Analysis Technology"

Hana Securities analyzed on the 13th that the overseas expansion partnership of Cytogen, a CTC liquid biopsy specialist company, will be expanded.

Cytogen is a specialized company with a liquid biopsy platform based on CTC (circulating tumor cells). CTCs are cancer cells that have detached from tumor tissue and are next-generation cancer-related biomarkers used in liquid biopsy. The company provides bio services in the process of pharmaceutical companies' anticancer drug development and operates diagnostic service businesses using liquid biopsy.

Jung Hyun Cho, a researcher at Hana Securities, explained, "Early cancer diagnosis through liquid biopsy mainly uses ctDNA (circulating tumor DNA), exosomes, and others," adding, "CTC specimens provide a wider range of analysis and more information, enabling more efficient bio services compared to other methods."

He continued, "CTCs, which are difficult to separate, exist in extremely small numbers?only about 1 to 10 cells?in 1 ml of blood where there are 1 billion blood cells," adding, "The low recovery rate due to this scarcity has been a limitation." Furthermore, he emphasized, "Cytogen developed a system capable of detecting CTCs based on gravity by utilizing a high-density microporous (HDM) chip made with its own patented technology."

Researcher Cho analyzed, "Cytogen can minimize damage to CTCs and enable live CTC separation technology," adding, "They have established the entire process of CTC liquid biopsy, handling all steps from blood preprocessing to CTC separation, detection and analysis, and cultivation, which is their competitive advantage."

He explained, "CTC-based liquid biopsy still has limited specimen separation technology and is a market with no global standardization," and "Only one company worldwide, ANGLE in the UK, has FDA approval for CTC detection devices." He added, "It is a time to pay attention to Cytogen’s independently developed CTC liquid biopsy platform," and "Cytogen is actively advancing into overseas markets."